JANX
Janux Therapeutics ($JANX): The "Pluvicto Killer" Thesis Is Alive, But the Hype Had to Die First
In the high-stakes world of biotechnology, "good" is often not enough when the market is pricing in "perfection." Yesterday, Janux Therapeutics ($JANX) released updated Phase 1 data that triggered a sharp >40% sell-off. The market’s simplistic algorithm—"No massive beat on the headline